on Heidelberg Pharma AG (isin : DE000A11QVV0)
Heidelberg Pharma to Showcase ADC Innovations at AACR 2025
Heidelberg Pharma AG will present its latest Antibody Drug Conjugates (ADCs) research at the AACR Annual Meeting 2025 in Chicago. The company, known for its innovative ADC technology, will highlight advancements in its Exatecan-based ADC platform, focusing on colorectal cancer treatment.
Dr. Sarah-Jane Neuberth will discuss preclinical studies on HDP-201, showing significant anti-tumor efficacy in GI malignancies with good tolerability. Meanwhile, Dr. Pablo Ruedas Batuecas will elaborate on pioneering NAMPT inhibitors as payloads, representing a potential leap forward in targeting both dividing and non-dividing cancer cells, addressing current therapy limitations.
The presentations include detailed overviews on overcoming tumor resistance using ADCs and computational modeling techniques for improved therapeutic delivery.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news